GENE ONLINE|News &
Opinion
Blog

Multiple Sclerosis
US Court Rules Novartis Blockbuster Multiple Sclerosis Drug’s Patent Invalid
2022-06-22
Janssen’s Multiple Sclerosis Drug Snags FDA Win after Besting Sanofi’s Blockbuster in Phase 3
2021-03-21
Biogen Strengthens its Grip on the Multiple Sclerosis Market with Another FDA Approval
2021-02-02
Novartis’ Kesimpta Notches FDA Approval as Targeted B-cell Therapy for Patients with Relapsing MS
2020-08-23
Sanofi Advances in Multiple Sclerosis Market with Principia Acquisition Deal
2020-08-18
Novartis Wins Five Simultaneous Drug Approvals in Japan
2020-07-06
Novartis Reveals Positive Ofatumumab Data for Treating Relapsing Forms of Multiple sclerosis
2020-06-07
Breakthrough Stem Cell Therapy Research Shows Repair in Multiple Sclerosis Damage
2020-05-24
Novartis Announces Mayzent Data that Shows Extended Benefit in Secondary Progressive MS
2020-04-21
Sanofi’s BTK Inhibitor Meets Primary Endpoint in Phase 2 Trial Amidst Criticism
2020-02-07
LATEST
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
2022-07-05
Breakthrough Zebrafish Genome Database Now Available
2022-07-05
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
2022-07-04
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
2022-07-04
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top